technetium tc-99m apcitide Report issue

Biologics Peptide Imaging Approved FDA Priority Review FDA
ChEMBL Drugs@FDA MeSH PubChem

Active Ingredient History

NOW
  • Now
Technetium Tc 99m apcitide is a radiopharmaceutical containing a metastable nuclear isomer of technetium-99. Upon radioactive decay with a half-life of 6 hours gamma-rays which can be detected using conventional equipment for X-ray diagnostics. Tc 99m contains the small-molecule synthetic peptide apcitide which binds to the PIIb/IIIa receptors on the surface of activated platelets, which are a major component in active thrombus formation. The localization of radioactivity may be recorded by gamma-ray detection camera. Tc 99m apcitide is indicated for scintigraphic imaging of acute venous thrombosis in the lower extremities in patients with signs and symptoms of acute blood clots. It is marketed by Bayer under tradename AcuTect.   NCATS

Chemistry

  • SMILES: [O--].[Na+].[99Tc+5].CC(=O)NCSC[C@H](NC(=O)CNC(=O)CNC(=O)[C@@H]1CSCC(=O)N[C@H](CC2=CC=C(O)C=C2)C(=O)N[C@@H](CSCCCN)C(=O)NCC(=O)N[C@@H](CC([O-])=O)C(=O)N1)C(=O)NCC(=O)N[C@@H](CSCNC(C)=O)C(=O)[N-]CC(=O)[N-]CC(=O)[N-][C@@H](C[S-])C(N)=O
  • InChIKey: NEIDEWFJOWALRO-YLXBGQBVSA-I
  • Mol. Mass: 1525.44
  • ALogP: Missing data
  • ChEMBL Molecule:
    technetium (99mtc) apcitide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Imaging: 99-MTC
  • Black Box: No
  • Availability: Discontinued
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

99mtc-apcitide | [99mtc]-p246 | 99mtc-p280 | (99m)technetium-p280 | acutect | p280 tc chelate | tc-99m-p280 | technetium (99mtc) apcitide | technetium tc 99m apcitide | technetium tc-99m apcitide | technetium tc 99m p280

Organizations (1)

Research & Development (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (1)


 

Venous Thrombosis (approved 1998)

Experimental Indications - Clinical Trial Phases 1-4 (0)

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue